PMID- 32243969
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 581
DP  - 2020 May 15
TI  - Engineering approaches for drug delivery systems production and characterization.
PG  - 119267
LID - S0378-5173(20)30251-9 [pii]
LID - 10.1016/j.ijpharm.2020.119267 [doi]
AB  - To find and to test the therapeutic effectiveness (and the limited adverse 
      effects) of a new drug is a long and expensive process. It has been estimated a 
      period of ten years and an expense of the order of one billion USD are required. 
      Meanwhile, even if a promising molecule has been identified, there is the need 
      for operative methods for its delivery. The extreme case is given by gene 
      therapy, in which molecules with tremendous in-vitro efficacy cannot be used in 
      practice because of the lack in useful vector systems to deliver them. Most of 
      the recent efforts in pharmaceutical sciences are focused on the development of 
      novel drug delivery systems (DDSs). In this review, the work done recently on the 
      development and testing of novel DDSs, with particular emphasis on the results 
      obtained by European research, is summarized. In the first section of the review 
      the DDSs are analyzed accordingly with their scale-size: starting from nano-scale 
      (liposomes, nanoparticles), up to the micro-scale (microparticles), until the 
      macroscopic world is reached (granules, matrix systems). In the following two 
      sections, non-conventional testing methods (mechanical methods and bio-relevant 
      dissolution methods) are presented; at last, the importance of mathematical 
      modeling to describe drug release and related phenomena is reported.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Barba, A A
AU  - Barba AA
AD  - Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy; 
      Dipartimento di Farmacia, Universita degli Studi di Salerno, via Giovanni Paolo 
      II, 132 84084 Fisciano (SA), Italy. Electronic address: aabarba@unisa.it.
FAU - Dalmoro, A
AU  - Dalmoro A
AD  - Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy; 
      Dipartimento di Farmacia, Universita degli Studi di Salerno, via Giovanni Paolo 
      II, 132 84084 Fisciano (SA), Italy.
FAU - Bochicchio, S
AU  - Bochicchio S
AD  - Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy; 
      Dipartimento di Farmacia, Universita degli Studi di Salerno, via Giovanni Paolo 
      II, 132 84084 Fisciano (SA), Italy.
FAU - De Simone, V
AU  - De Simone V
AD  - Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy; 
      Dipartimento di Farmacia, Universita degli Studi di Salerno, via Giovanni Paolo 
      II, 132 84084 Fisciano (SA), Italy.
FAU - Caccavo, D
AU  - Caccavo D
AD  - Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy; 
      Dipartimento di Farmacia, Universita degli Studi di Salerno, via Giovanni Paolo 
      II, 132 84084 Fisciano (SA), Italy; Dipartimento di Ingegneria Industriale, 
      Universita degli Studi di Salerno, via Giovanni Paolo II, 132 84084 Fisciano 
      (SA), Italy.
FAU - Iannone, M
AU  - Iannone M
AD  - Dipartimento di Farmacia, Universita degli Studi di Salerno, via Giovanni Paolo 
      II, 132 84084 Fisciano (SA), Italy; Dipartimento di Ingegneria Industriale, 
      Universita degli Studi di Salerno, via Giovanni Paolo II, 132 84084 Fisciano 
      (SA), Italy.
FAU - Lamberti, G
AU  - Lamberti G
AD  - Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy; 
      Dipartimento di Ingegneria Industriale, Universita degli Studi di Salerno, via 
      Giovanni Paolo II, 132 84084 Fisciano (SA), Italy. Electronic address: 
      glamberti@unisa.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200331
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Drug Carriers)
SB  - IM
MH  - *Chemical Engineering
MH  - Chemistry, Pharmaceutical/*methods
MH  - Drug Carriers/*chemistry
MH  - Drug Compounding/*methods
MH  - Drug Liberation
MH  - Models, Biological
MH  - Particle Size
OTO - NOTNLM
OT  - Drug delivery
OT  - Hydrogel
OT  - Innovation in Europe
OT  - Microvectors
OT  - Modeling
OT  - Nanovectors
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/04/04 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/03/01 00:00 [received]
PHST- 2020/03/22 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - S0378-5173(20)30251-9 [pii]
AID - 10.1016/j.ijpharm.2020.119267 [doi]
PST - ppublish
SO  - Int J Pharm. 2020 May 15;581:119267. doi: 10.1016/j.ijpharm.2020.119267. Epub 
      2020 Mar 31.